Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR
Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
November 2025
|
| In: |
Clinical research in cardiology
Year: 2025, Volume: 114, Issue: 11, Pages: 1606-1615 |
| ISSN: | 1861-0692 |
| DOI: | 10.1007/s00392-025-02749-7 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00392-025-02749-7 |
| Author Notes: | David Hesselbarth, Michelle D’Orazio, Giovanni Ciccarone, Diona Gjermeni, Carina Jülch, Marius Wessinger, Mariya Maslarska, Jonathan Rilinger, Ingo Hilgendorf, Dennis Wolf, Klaus Kaier, Daniel Duerschmied, Torben Pottgiesser, Constantin von zur Mühlen, Dirk Westermann, Christoph B. Olivier |
| Summary: | Patients after transcatheter aortic valve replacement (TAVR) are at increased risk of both major adverse cardiac events (MACE), including ischemic and thrombotic complications, as well as significant bleeding. Given this delicate balance between prothrombotic and hemorrhagic risk, the assessment of hemostatic markers might help identify patients at increased risk. |
|---|---|
| Item Description: | Online veröffentlicht: 6. Oktober 2025 Gesehen am 04.12.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1861-0692 |
| DOI: | 10.1007/s00392-025-02749-7 |